Female sexual dysfunction encompasses low libido, impaired arousal, anorgasmia, and dyspareunia — driven by hormonal imbalances, reduced central dopamine/melanocortin signaling, vascular insufficiency in genital tissue, and psychogenic factors. Peptide research addresses both the central arousal deficit and the peripheral vascular and hormonal components.
1. PT-141 (Bremelanotide) — Central Arousal Activation
PT-141 is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. It activates hypothalamic MC3R/MC4R receptors to directly stimulate sexual desire and arousal at the brain level — bypassing hormonal status. Unlike hormone therapy, PT-141 works regardless of estrogen or testosterone levels.
Dosing Protocol: 1.75 mg SubQ 45 minutes before sexual activity (FDA-approved dose). Lower doses (0.5–1 mg) can be used to reduce side effects (nausea, flushing). Not for daily use.
2. Kisspeptin — Hormonal Drive / GnRH Restoration
Kisspeptin regulates GnRH and LH pulsatility, which governs estrogen and progesterone cycles. In women with hypogonadotropic hypogonadism or suppressed hormonal function, kisspeptin directly restores the hypothalamic signaling driving libido and sexual responsiveness. It also has direct pro-sexual effects via limbic system kisspeptin receptors.
Dosing Protocol: 50–100 mcg SubQ 2–3x weekly. Clinical doses vary; SubQ protocols at 50 mcg appear to produce meaningful LH stimulation in women.
3. BPC-157 — Genital Vascular / Tissue Repair
Adequate genital blood flow and mucosal health are prerequisites for arousal and lubrication. BPC-157 promotes angiogenesis and NO production in vascular tissue, improving genital blood flow responses. It also has anti-inflammatory effects relevant to dyspareunia caused by vaginal tissue inflammation.
Dosing Protocol: 250–500 mcg SubQ daily. Can be administered near pelvic vasculature. Cycle: 6–8 weeks.
4. Oxytocin — Intimacy / Arousal Amplification
Oxytocin — the “bonding hormone” — amplifies genital sensation, enhances orgasmic intensity, and deepens emotional connection during intimacy. Intranasal oxytocin prior to sexual activity has demonstrated increased arousal and satisfaction in clinical research, and directly enhances the response to physical stimulation.
Dosing Protocol: 20–40 IU intranasal (2–4 sprays of 10 IU/spray) 20–30 minutes before sexual activity. Compounded SubQ oxytocin: 2–5 IU SubQ as needed.
PT-141 activates the central brain arousal pathway regardless of hormonal status. Kisspeptin restores the underlying hormonal drive when GnRH/LH suppression is the root cause. BPC-157 optimizes the peripheral vascular response required for physical arousal. Oxytocin amplifies sensation, emotional connection, and orgasmic response in the moment.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).